Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies

Bone Marrow Transplantation

Volumn 19, Issue 12, 1997, Pages 1233-1238

  Uberti, J P ^a   Silver, S M ^a   Adams, P T ^a   Jacobson, P ^a   Scalzo, A ^a   Ratanatharathorn, V ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acute graft versus host disease; Allogeneic bone marrow transplantation; Hematologic malignancies; Methotrexate; Tacrolimus

Indexed keywords

METHOTREXATE; TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FAMILY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; PROBABILITY; RELAPSE; SIBLING; SURVIVAL;

EID: 0030873602     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700813     Document Type: Article

References (29)

1. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-72.
2. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
3. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980-1987.
4. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
5. Storb R, Martin P, Deeg HJ et al. Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. Blood 1992; 79: 3091-3092.
6. Storb R, Sanders JE, Pepe M et al. Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. Blood 1991; 78: 1144-145.
7. Storb R, Pepe M, Deeg HJ et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992; 80: 560-561.
8. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
9. Storb R, Pepe M, Anasetti C et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037-1045.
10. von Bueltzingsloewen A, Belanger R, Perreault C et al. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. Blood 1993; 81: 849-855.
11. Kelly PA Burckart GJ Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995; 52: 1521-1535.
12. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746-794.
13. Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. J Immunol 1994; 153: 1836-1846.
14. Storb R, Raff RF, Appelbaum FR et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 1993; 56: 800-807.
15. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-3753.
16. Fay JW, Wingard JR, Antin JH et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87: 3514-3519.
17. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
18. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
19. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
20. Ratanatharathorn V, Karanes C, Lum LG et al. Allogeneic bone marrow transplantation in high risk myeloid disorders using busulfan, cytosine arabinoside, and cyclophosphamide (BAC) - a new and effective regimen. Bone Marrow Transplant 1992; 9: 49-55.
21. Grenier FC, Luczkiw J, Bergmann M et al. Whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991; 23: 2748-2749.
22. Gluksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
23. Dixon WJ. BMDP Statistical Software. University of California Press: Berkley, 1990.
24. Mehta C, Patel N. Statxact-Turbo: Statistical Software for Exact Nonparametric Inference. Cytel Software Corporation: Cambridge, 1992.
25. McDonald GB, Sharma P, Matthews DE. et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
26. Bishop DK, Li W. Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. J Immunol 1992; 148: 1049-1054.
27. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
28. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992;80: 1838-1845.
29. Przepriorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-4389.